<DOC>
	<DOCNO>NCT00126620</DOCNO>
	<brief_summary>RATIONALE : Sorafenib erlotinib may stop growth tumor cell block blood flow tumor block enzyme need cell growth . PURPOSE : This phase I trial study side effect best dose sorafenib erlotinib treat patient metastatic unresectable solid tumor .</brief_summary>
	<brief_title>Sorafenib Erlotinib Treating Patients With Metastatic Unresectable Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose recommended phase II dose sorafenib erlotinib patient metastatic unresectable solid tumor . Secondary - Determine optimal biologically effective dose regimen lead hypophosphorylation epidermal growth factor receptor ( EGFR ) , ERK , Akt , vascular endothelial growth factor receptor ( VEGFR ) , inhibition angiogenesis apoptosis tolerable toxicity patient . - Correlate pharmacokinetic profile regimen toxicity biological activity patient . - Determine , preliminarily , antitumor activity regimen patient . - Correlate phosphorylation status EGFR , ERK , Akt , VEGFR antitumor activity regimen patient . OUTLINE : This multicenter , open label , non-randomized , dose-escalation study . Patients receive oral sorafenib alone twice daily day -6 0* . Patients receive oral sorafenib twice daily oral erlotinib daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . NOTE : *Not consider part course 1 ; consider `` run-in '' period . Cohorts 3-6 patient receive escalate dos sorafenib erlotinib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . An additional 10 patient treated MTD . After completion study treatment , patient follow 4 week least annually thereafter . PROJECTED ACCRUAL : A total 16-28 patient accrue study within 5-14 month .</detailed_description>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor Metastatic unresectable disease Standard curative palliative measure exist OR longer effective Measurable disease radiography ( patient treat maximum tolerate dose [ MTD ] ) Tumor accessible serial biopsy ( patient treat MTD ) No know brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy More 12 week Hematopoietic WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 No bleed diathesis coagulopathy Hepatic Bilirubin normal AST ALT ≤ 2.5 time ULN PT INR ≤ 1.5 unless fulldose warfarin Renal Creatinine normal OR Creatinine clearance ≥ 60 mL/min Cardiovascular No uncontrolled hypertension ( i.e. , systolic blood pressure [ BP ] &gt; 140 mm Hg diastolic BP &gt; 90 mm Hg despite medication ) No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Ophthalmic No abnormality cornea , include follow : Dry eye syndrome Sjögren 's syndrome Congenital abnormality ( e.g. , Fuch 's dystrophy ) Abnormal slitlamp examination use vital dye ( e.g. , fluorescein BengalRose ) Abnormal corneal sensitivity test ( e.g. , Schirmer test similar tear production test ) Gastrointestinal No active peptic ulcer disease would impair ability swallow pills No gastrointestinal tract disease result inability take oral medication requirement IV alimentation Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Willing undergo serial biopsy , positron emission tomography , CT scanning ( patient treat MTD ) No ongoing active infection No significant traumatic injury within past 3 week No history allergic reaction drug similar chemical biological composition study drug No psychiatric illness social situation would preclude study compliance No condition would impair ability swallow pills No uncontrolled illness PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent prophylactic hematopoietic colonystimulating factor Chemotherapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy ( except low dose , nonmyelosuppressive radiotherapy ) recover Surgery More 3 week since prior major surgery No prior surgical procedure affect absorption Other No prior sorafenib erlotinib No prior agent target Raf , vascular endothelial growth factor ( VEGF ) , VEGF receptor , epidermal growth factor receptor No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient No concurrent enzymeinducing antiepileptic drug ( e.g. , phenytoin , carbamazepine , phenobarbital ) No concurrent CYP3A4 inducer ( e.g. , rifampin Hypericum perforatum [ St. John 's wort ] ) No concurrent anticancer therapy Concurrent prophylactic anticoagulation therapy ( e.g. , lowdose warfarin ) allow provide PT INR &lt; 1.1 time upper limit normal ( ULN ) Concurrent fulldose anticoagulant ( e.g. , warfarin ) PT INR &gt; 1.5 allow provide follow criterion meet : Patient range INR ( 23 ) stabledose oral anticoagulant OR stabledose low molecular weight heparin No active bleeding OR pathological condition would confer high risk bleeding ( e.g. , tumor involve major vessel know varix )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>